TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06567327
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin oral tablets
Study: NCT06052059
Drug: IV Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching IV tulisokibart
Study: NCT06052059
Drug: SC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching SC tulisokibart
Study: NCT05122377
Drug: 3M GnRHa
Approvals — FDA: no, EMA: no, PMDA: no
Description: This was a real world, observational study of adjuvant endocrine therapy with GnRHa for OFS in postoperative, premenopausal women with endocrine responsive breast cancer. Patients will receive treatment per GnRHa commercial label instruction: leuprorelin, goserelin, leuprorelin from local like: acetate microspheres sustained for injection(boennuokang), leuprorelin acetate microspheres for injection(beiyi).
Study: NCT03885245
Drug: L-ctirulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
Study: NCT05327751
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle.
Study: NCT05327751
Drug: Capecitabine-based chemotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine-based chemotherapy
Study: NCT04551768
Drug: 50 mg/mL Virazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/mL Virazole aerosolized and administered over 1 hour twice a day for up to 6 days.
Study: NCT04551768
Drug: 100 mg/mL Virazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/mL Virazole aerosolized and administered over 30 minutes twice a day for up to 6 days.
Study: NCT04571216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections
Study: NCT04750278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID
Study: NCT00001070
Drug: Oral Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05118763
Drug: INNA-051
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid for intranasal administration
Study: NCT05357755
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered orally as delayed release tablets.
Study: NCT04421352
Drug: CS1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;~In the dose expansion part, more SCLC patients will be assigned.
Study: NCT05912075
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m2 bid for 5 days per week (From Monday to Friday) for 25 days will be given concomitantly during the 5 weeks of radiotherapy
Study: NCT05912075
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: given every 2 weeks for 9 cycles, starting 10 days after the last session of short course radiotherapy
Study: NCT05912075
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 3 weeks for 6 cycles, starting 10 days after the last session of short course radiotherapy.
Study: NCT05853367
Drug: MK-0472
Normalized name: vitamin MK 7
DrugBank: MK-0752 (DB12852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT05853367
Drug: MK-1084
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT05667818
Drug: Amlodipine besylate tablets (trade name: Norfloxacin ®）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specification: 5 mg Batch No.: FX3445 Content: 100.2% Expiry date: January 2027 Storage conditions: dark and sealed Manufacturer: Pfizer Inc. Provider: Overseas Pharmaceuticals, Ltd. Take one tablet once a day.
Study: NCT05119686
Drug: AR882 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Capsule
Study: NCT05119686
Drug: AR882 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Capsule
Study: NCT05119686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Solid Oral Capsule Placebo
Study: NCT04783870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06574828
Drug: BIIB091
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06574828
Drug: BIIB091-matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT06015568
Drug: MCLA-129: 1500mg or 2000mg IV Q2W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 28 days is a cycle until disease progression, death, initiation of new anti-tumor treatment, loss of follow-up, or voluntary withdrawal occurs
Study: NCT06263244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05193968
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
Study: NCT05193968
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
Study: NCT06467539
Drug: DAOIB plus AO
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, for 24 weeks
Study: NCT06467539
Drug: DAOIB plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, for 24 weeks
Study: NCT05987332
Drug: IDE196
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed orally, twice daily
Study: NCT06801379
Drug: Inhaled Melatonin (100 μg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An orally inhaled formulation of melatonin delivered by pressurised metered dose inhaler (pMDI) to be taken before bedtime. The pMDI will deliver a total of 100 μg of inhaled melatonin (2 x 50 μg/actuation). The investigational product is produced under Good Manufacturing Practice by Ab Initio Pharma Pty Ltd, a GMP certified manufacturer of pharmaceutical products.
Study: NCT06801379
Drug: Oral Melatonin (4 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two orally ingested tablets each containing 2 mg of melatonin (4 mg total) to be taken before bedtime. The investigational product is manufactured under Good Manufacturing Practice and is compliant with the TGA Therapeutic Order #101 that stipulates quality control requirements for capsule and pill-based products used in Australia.
Study: NCT05964920
Drug: Saline + Resistance exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo injections one at baseline and one week 3 and10 weeks of supervised, structured, progressive resistance training.
Study: NCT05964920
Drug: Testosterone Undecanoate + Resistance exercise training
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two testosterone undecanoate injections, 1000 mg/4 ml at baseline, 500 mg/2 ml at week 3 and 10 weeks of supervised, structured, progressive resistance training.
Study: NCT06345599
Drug: Immunotherapy:Granulocyte macrophage-colony stimulating factor(GM-CSF)、Cadumilimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF treatment: GM-CSF 200μg was started on the day of radiotherapy, and was subcutaneously injected daily for 7 consecutive days; d1-d7 Cadumilimab: use 375mg of cadumilimab within one week after radiotherapy
Study: NCT06001853
Drug: DSMO Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 6 months, patients randomized to Arm B: DMSO will be unblinded and re-assigned to Arm A: treatment then be followed for 12 months.
Study: NCT05768529
Drug: U16
Normalized name: LU16 (ISBT symbol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered before U16 treatment.
Study: NCT06011980
Drug: Growth Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: growth inhibitors for 250-500μg/h, ivgtt. for 5 days
Study: NCT05682599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06041152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of placebo separated by one week.
Study: NCT05411991
Drug: Intravenous bumetanide TID
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An intravenous bolus of bumetanide is administered TID, with dosing according to eGFR: 2 mg for an eGFR \>45 mL/min/1.73m²; 3 mg for an eGFR 30-45 mL/min/1.73m²; and 4 mg for an eGFR \<30 mL/min/1.73m². At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), a dose of 4 mg TID is used.
Study: NCT05411991
Drug: Oral chlorthalidone OD
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In case of hypernatremia (\>145 mmol/L) or low eGFR (\<30 mL/min/1.73m²), oral chlorthalidone 50 mg OD is added to the diuretic treatment. At any time diuretic resistance is encountered (persistent clinical signs of fluid overload with UNa \<80 mmol/L), oral chlorthalidone is provided at a dose of 100 mg OD. Chlorthalidone is never administered in case of hypotonic hyponatremia with serum sodium concentration \<135 mmol/L.
Study: NCT04761614
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04761614
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IVPB
Study: NCT04687540
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are under influence of tocilizumab since the effect of the drug will last for 4 weeks. Participants will be infused with saline at study visit 2 (study day 21). Placebo to tocilizumab will be saline (NaCl 0.9%) as tocilizumab is a colorless solution and has to be diluted with NaCl 0.9% prior to administration
Study: NCT05223803
Drug: Systemic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All systemic therapy is provided as best prescribed for patient per their medical oncologist.
Study: NCT05327595
Drug: LY3549492
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05327595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05176639
Drug: VRDN-001 Phase 3 Cohort (THRIVE)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 IV Infusions of veligrotug (VRDN-001) 10mg/kg
Study: NCT05176639
Drug: VRDN-001 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 IV Infusions of veligrotug (VRDN-001) placebo
Study: NCT05961189
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard of care, 5 days of drug per manufacturer's instructions.
Study: NCT06551298
Drug: Atorvastatin Calcium 20Mg Tab
Normalized name: ATORVASTATIN CALCIUM 20MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin Calcium Tablets (20mg, qn)+Low Fat Diet
Study: NCT05186051
Drug: ZYIL1 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLRP3 inflammasome inhibitor
Study: NCT06269393
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group: 10 mg/kg of placebo on Day 1, followed by 20 mg/kg, q3W of placebo for the following 3 infusions.10 mg/kg of IBI311 at Week 12, followed by 20 mg/kg, q3W of IBI311 for the remaining 3 infusions.
Study: NCT06269393
Drug: IBI311
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI311 group: 10 mg/kg of IBI311 on Day 1, followed by 20 mg/kg, q3W of IBI311 for the remaining 7 infusions; .
Study: NCT03585946
Drug: Site specific standard of care comparison
Normalized name: SOLO SITE WOUND CARE GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
Study: NCT06372314
Drug: Total parenteral nutrition (TPN): this is total nutrition provided by central vein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
Study: NCT05249387
Drug: A-967079 and BAM8-22 application
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT05249387
Drug: A-967079 and BAM8-22 application after 5 minutes.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml). BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied 5 minutes after to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT05249387
Drug: A-967079 application.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A-967079 solution (in PBS 0.5 mg/ml, subcutaneous injection of 0.1ml) will be applied to a previously determined area on the volar forearm
Study: NCT05249387
Drug: Vehicle and BAM8-22 application.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle (in PBS, subcutaneous injection of 0.1ml) and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules
Study: NCT05566626
Drug: Mydriacyl Ophthalmic Product
Normalized name: Mydriacyl Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mydriatic drops before retinoscopy
Study: NCT05711017
Drug: Huashibaidu granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).
Study: NCT06267820
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: analgesia
Study: NCT05576961
Drug: RX-af01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment： vancomycin: 125mg po, tid, D-6 to D-3 RX-af01: 2 capsules, bid, po, D-2 to D0 Treatment (Every 3 weeks) RX-af01: 1 capsule, bid, po, every day Toripalimab: 240mg, ivdrip, D1, every 3 weeks.
Study: NCT05576961
Drug: Mixed bacteria
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment： vancomycin: 125mg po, tid, D-5 to D-3
Study: NCT06066255
Drug: Thymoglobulin Injectable Product
Normalized name: Thymoglobulin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: single intravenous injection of thymoglobulin
Study: NCT05711017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
Study: NCT03613792
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Opioid analgesic
Study: NCT03613792
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Opioid analgesic
Study: NCT05098366
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mL/kg (max 1000mL) normal saline bolus plus a normal saline flush
Study: NCT05649696
Drug: Recombinant Staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT05649696
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of normal saline is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT06378060
Drug: Modified transplantation system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning regimen: fludarabine 30mg/m2×5\~6d,cyclophosphamide 50mg/kg×2d, melphalan 100mg/m2×1d aGVHD prophylaxis: PTCY 25mg/kg×2d, ATG 4.5mg/kg total, MMF 15mg/kg +5d\~+35d, Ruxolitinib 5mg bid -1d\~+50d and 2.5mg bid +51d\~+110d, CSA
Study: NCT05057858
Drug: co-formulated 300 mg TDF/ 200mg FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized into 1 of 3 groups to receive a controlled number of doses of a single tablet co-formulated 300 mg TDF/ 200mg FTC
Study: NCT04999449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal saline placebo
Study: NCT05013632
Drug: Antiviral Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral medications indicated for the treatment of mild to severe COVID-19
Study: NCT06302049
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT05200299
Drug: mFOLFOX6 OR CapeOx
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6(oxaliplatin 85 mg/m2, folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-48 hour continuous infusion on day 1)~CapeOx(Oxaliplatin 130 mg/m2 intravenous infusion on day 1,Capecitabine 1000 mg/m2 twice daily PO for 14 days)
Study: NCT05341050
Drug: TKI
Normalized name: Catkin
Approvals — FDA: no, EMA: no, PMDA: no
Description: halve dose of 2G-TKI for 12 months and then withdrawal for 12 months
Study: NCT04948827
Drug: SBP-9330
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBP-9330 oral capsules
Study: NCT04948827
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules
Study: NCT04611139
Drug: SP-2577
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral doses
Study: NCT05208827
Drug: The placebo(not contain vitamin D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills that looked, colored and tasted like vitamin D in the control group, but contained only starch and vegetable oil and no vitamin D.
Study: NCT05982197
Drug: Standard Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation for prevention radiation induced oral mucositis
Study: NCT05028829
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo
Study: NCT05543928
Drug: CTAP101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTAP101 Capsules is an extended-release (ER) oral formulation of calcifediol which was approved as Rayaldee® ER Capsules in June 2016 by the United States (US) Food and Drug Administration (FDA) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency (VDI), defined as serum total 25-hydroxyvitamin D levels less than 30 ng/mL.
Study: NCT05543928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05018676
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
Study: NCT04273997
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment
Study: NCT06653842
Drug: QTORIN 3.9% rapamycin anhydrous gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: QTORIN 3.9% Rapamycin Anhydrous Gel
Study: NCT05312970
Drug: Varithena®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varithena® (polidocanol injectable foam) 1%
Study: NCT05387798
Drug: RAD011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)
Study: NCT06398444
Drug: Lutetium[177Lu] Oxodotreotide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 7.4GBq (200mCi) Lutetium\[177Lu\] Oxodotreotide Injection every 8 weeks.
Study: NCT06225596
Drug: BT8009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.
Study: NCT06225596
Drug: BT8009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.
Study: NCT06225596
Drug: BT8009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.
Study: NCT05355077
Drug: JT001 200mg Bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
Study: NCT05355077
Drug: JT001 400mg Bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
Study: NCT05355077
Drug: JT001 600mg Bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
Study: NCT05599347
Drug: Azithromycin Pill
Normalized name: azithromycin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet - 500 mg azithromycin (as dihydrate)
Study: NCT05296798
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: A luteinizing hormone-releasing hormone (LHRH) agonist will be administered every 28 days to pre- and peri-menopausal women and all male participants while receiving giredestrant in Arm B. An LHRH agonist may be administered to male participants and pre- and peri-menopausal female participants receiving tamoxifen in Arm A, and should be administered to those receiving an aromatase inhibitor in Arm A. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer. The LHRH agonist will be administered according to local prescribing information.
Study: NCT05296798
Drug: Optional Endocrine Therapy of Investigator's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: For participants in Arm A, optional endocrine therapy of investigator's choice is allowed based on the standard of care, and it can include an aromatase inhibitor or tamoxifen with or without an LHRH agonist, or gonadal ablation. The decision to include or exclude this option must be made prior to randomization.